Establishing guidelines for CAR-T cells： challenges and considerations

• Published in: Science China. Life sciences Vol. 59; no. 4; pp. 333 - 339
• Main Authors: Wang, Wei, Qin, Di-Yuan, Zhang, Bing-Lan, Wei, Wei, Wang, Yong-Sheng, Wei, Yu-Quan
• Format: Journal Article Book Review
• Language: English
• Published: Beijing Science China Press 01.04.2016; Springer Nature B.V
• Subjects: Biomedical and Life Sciences; Cell Culture Techniques - methods; Cell Culture Techniques - standards; Flow Cytometry; Guidelines as Topic; Humans; Immunotherapy, Adoptive - methods; Immunotherapy, Adoptive - standards; Life Sciences; Neoplasms - genetics; Neoplasms - immunology; Neoplasms - therapy; Receptors, Antigen, T-Cell - genetics; Receptors, Antigen, T-Cell - immunology; Receptors, Antigen, T-Cell - metabolism; Recombinant Fusion Proteins - genetics; Recombinant Fusion Proteins - immunology; Recombinant Fusion Proteins - metabolism; Review; T-Lymphocytes - immunology; T-Lymphocytes - metabolism; T-Lymphocytes - transplantation; Transfection - methods; Transfection - standards; T细胞; 免疫疗法; 受体基因; 基因治疗; 恶性血液病; 抗原特异性; 指南; 细胞毒性; chimeric antigen receptor; CAR-T cells; guideline; cancer immunotherapy
• ISSN: 1674-7305; 1869-1889; 1869-1889
• DOI: 10.1007/s11427-016-5026-5

T cells, genetically modified by chimeric antigen receptors（CAR-T）, are endowed with specificity to a desired antigen and are cytotoxic to cells expressing the targeted antigen. CAR-T-based cancer immunotherapy is a promising therapy for curing hematological malignancy, such as acute lymphoid leukemia, and is promising for extending their efficacy to defeat solid tumors. To date, dozens of different CAR-T cells have been evaluated in clinical trials to treat tumors; this necessitates the establishment of guidelines for the production and application of CAR-T cells. However, it is challenging to standardize CAR-T cancer therapy because it involves a combination of gene therapy and cell therapy. In this review, we compare the existing guidelines for CAR-T cells and discuss the challenges and considerations for establishing guidance for CAR-T-based cancer immunotherapy.